NEW
Stock Screener with Intrinsic Value
Royalty Pharma plc (RPRX)
Last Price$30.8(0.6%)
Market Cap$13.8B
LTM P/E
12.0x
EPS growth
14.5%
PEGY
0.7x
Peter Lynch Fair Value
$43.9
Undervalued (Peter Lynch formula)
42.7%
Stock quality
7/10
Good
RPRX Peter Lynch Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
RPRX EPS growth & Dividend Yield
Crunching data... Almost there!
RPRX vs Peer Set: Peter Lynch Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for RPRX
Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Royalty Pharma plc fair value by Peter Lynch formula?
As of Jan 17, 2025, Royalty Pharma plc's fair value using the Peter Lynch formula is $43.9 per share. The current price of $30.8 suggests Royalty Pharma plc may be undervalued by this metric.
What is Royalty Pharma plc Price to Earnings (P/E) ratio?
As of Jan 17, 2025, Royalty Pharma plc's P/E ratio is 12.0x. This is calculated by dividing the current share price of $30.8 by the Earnings per Share (EPS) for the trailing twelve months, which is $3.0. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
What is Royalty Pharma plc earnings per share (EPS)?
Royalty Pharma plc earnings per share (EPS) for the twelve months ending Jan 17, 2025, was $3.0, a 14.5% growth year-over-year.